1. Signaling Pathways
  2. Protein Tyrosine Kinase/RTK
  3. Tie
  4. Tie2 Isoform

Tie2

 

Tie2 Related Products (18):

Cat. No. Product Name Effect Purity
  • HY-10331
    Regorafenib
    Inhibitor 99.93%
    Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/Flt-1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity.
  • HY-10331A
    Regorafenib monohydrate
    Inhibitor 99.96%
    Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/Flt-1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity.
  • HY-100556
    Tie2 kinase inhibitor 1
    Inhibitor 99.90%
    Tie2 kinase inhibitor 1 (compound 5) is a potent, selective Tie2 kinase inhibitor with an IC50 of 250 nM. Tie2 kinase inhibitor 1 has anti-cancer activity.
  • HY-108333
    SB-633825
    Inhibitor 98.52%
    SB-633825 is a potent and ATP-competitive inhibitor of TIE2, LOK (STK10) and BRK with IC50s of 3.5 nM, 66 nM, 150 nM, respectively. SB-633825 can inhibit cancer cell growth and angiogenesis.
  • HY-100756
    BAY-826
    Inhibitor 99.94%
    BAY-826 is a selective and potent TIE-2 inhibitor with a Kd of 1.6 nM, respectively.
  • HY-164529
    SJ-C1044
    Inhibitor
    SJ-C1044 is an orally available pan-RAF inhibitor with immunomodulatory and anti-tumor activities. SJ-C1044 inhibits wild-type BRAF, wild-type CRAF, and BRAF (V600E) with IC50 values ??of 331, 257, and 187 nM, respectively. SJ-C1044 inhibits tumor cell proliferation by inhibiting kras activation and MEK-ERK phosphorylation. In addition, SJ-C1044 also has a certain inhibitory effect on VEGFR2/KDR/Flk-1, TIE2, and CSF1R, with IC50 values ??of 100, 23, and 235 nM, respectively. SJ-C1044 improves the tumor immune microenvironment by inhibiting angiogenesis and regulating macrophage function. SJ-C1044 can be used in the study of colorectal cancer.
  • HY-15973
    BSF-466895
    Inhibitor
    BSF-466895(A-422885.66) is a Tie2 inhibitor with an IC50 of 5 nM and it can also inhibit Tie1.
  • HY-100394
    NVP-BAW2881
    Inhibitor 98.54%
    NVP-BAW2881 (BAW2881) is a potent and selective VEGFR2/KDR/Flk-1 inhibitor with an IC50 of 4 nM.
  • HY-12572
    TIE-2/VEGFR-2 kinase-IN-2
    Inhibitor 99.79%
    TIE-2/VEGFR-2 kinase-IN-2 is a potent dual VEGFR2/KDR/Flk-1 and Tie-2 inhibitor with pIC50 values of 8.61 and 8.56, respectively. TIE-2/VEGFR-2 kinase-IN-2 is an anti-angiogenic agent and can be used for cancer research.
  • HY-112423
    CE-245677
    Inhibitor 98.14%
    CE-245677 is a potent reversible inhibitor of Tie2 and TrkA/B kinases with a cellular IC50s of 4.7 and 1 nM.
  • HY-125741
    GW768505A free base
    Inhibitor 98.66%
    GW768505A free base is a potent dual inhibitor of VEGFR2/KDR/Flk-1 (VEGFR2/KDR/Flk-1) and Tie-2, with a pIC50 of 7.81 for VEGFR2/KDR/Flk-1. GW768505A free base has anti-angiogenic activity。
  • HY-112294
    TIE-2/VEGFR-2 kinase-IN-1
    Inhibitor 99.91%
    TIE-2/VEGFR-2 kinase-IN-1 is used for the synthesis of TIE-2 and/or VEGFR-2 inhibitors, extracted from patent WO2003022852, example 14. TIE-2/VEGFR-2 kinase-IN-1 is used for the study of diseases associated with inappropriate angiogenesis.
  • HY-10331B
    Regorafenib mesylate
    Inhibitor
    Regorafenib (BAY 73-4506) mesylate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/Flt-1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib mesylate shows very robust antitumor and antiangiogenic activity.
  • HY-112475
    Flt-3 Inhibitor III
    Inhibitor
    Flt-3 Inhibitor III is a potent and selective FLT3 kinase inhibitor with an 50 of 50 nM. Flt-3 Inhibitor III shows less active against other kinases. Flt-3 Inhibitor III has anticancer effects.
  • HY-156638
    TIE-2/VEGFR-2 kinase-IN-5
    Inhibitor
    TIE-2/VEGFR-2 kinase-IN-5 is an anti-angiogenic agent. TIE-2/VEGFR-2 kinase-IN-5 also is a potent TIE-2 and VEGFR-2 tyrosine kinase inhibitor with pIC50 values of 7.78 nM and 8.11 nM, respectively. TIE-2/VEGFR-2 kinase-IN-5 can be used for the research of angiogenesis.
  • HY-156635
    TIE-2/VEGFR-2 kinase-IN-3
    Inhibitor
    TIE-2/VEGFR-2 kinase-IN-3, benzimidazole, is a potent TIE-2 and VEGFR-2 tyrosine kinase receptors inhibitors with IC50 values of 6.9 nM and 3.5 nM, respectively. TIE-2/VEGFR-2 kinase-IN-3 can be used for the research of angiogenesis.
  • HY-156637
    TIE-2/VEGFR-2 kinase-IN-4
    Inhibitor
    TIE-2/VEGFR-2 kinase-IN-4, benzimidazole, is a potent TIE-2 and VEGFR-2 tyrosine kinase receptors inhibitors with IC50 values of 5.2 nM and 5.1 nM, respectively. TIE-2/VEGFR-2 kinase-IN-4 can be used for the research of angiogenesis.
  • HY-113571
    Tie2 kinase inhibitor 2
    Inhibitor
    Tie2 kinase inhibitor 2 (compound 7) is a selective Tie2 kinase inhibitor with an IC50 value of 1 μM. Tie2 kinase inhibitor 2 inhibits endothelial cell tube formation, and can be used for Tie2-mediated angiogenic disorders research.